NCT03526289View on ClinicalTrials.gov

GIP/GLP-1 Co-Activity in Subjects With Overweight and Type 2 Diabetes: Lowering of Food Intake

NACompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 8, 2017

Primary Completion Date

October 24, 2018

Study Completion Date

October 24, 2018

Conditions
Type 2 Diabetes MellitusOverweight and Obesity
Interventions
BIOLOGICAL

GIP1-42 infusion

5-hour GIP1-42 infusion (time point 0-300 minutes)

OTHER

Saline

5-hour infusion of saline (placebo) (time point 0-300 minutes)

Trial Locations (1)

DK-2900

Center for diabetes research, Hellerup

Sponsors

Collaborators (1)

Zealand Pharma
All Listed Sponsors
collaborator

Zealand Pharma

INDUSTRY

lead

University Hospital, Gentofte, Copenhagen

OTHER

NCT03526289 - GIP/GLP-1 Co-Activity in Subjects With Overweight and Type 2 Diabetes: Lowering of Food Intake | Biotech Hunter | Biotech Hunter